G. Ugoh, A. Linfante, Allison J. Good, Janice M. Wilson, Kathleen Kroger
Bazex syndrome, also known as Acrokeratosis paraneoplastica, is a paraneoplastic disorder characterized by erythematous psoriasiform plaques involving the nose, ears, and acral sites. Although classically associated with squamous cell carcinomas of the upper aerodigestive tract, it has also been reported in association with adenocarcinoma, genitourinary tumors, multiple myeloma, and rarely, peripheral T-cell lymphoma and follicular lymphoma in-situ. Herein, we present a patient with Bazex syndrome associated with angioimmunoblastic T-cell lymphoma (AITL), a rare association not previously reported in the literature.
{"title":"Bazex Syndrome Associated with Angioimmunoblastic T-cell Lymphoma","authors":"G. Ugoh, A. Linfante, Allison J. Good, Janice M. Wilson, Kathleen Kroger","doi":"10.25251/skin.7.3.14","DOIUrl":"https://doi.org/10.25251/skin.7.3.14","url":null,"abstract":"Bazex syndrome, also known as Acrokeratosis paraneoplastica, is a paraneoplastic disorder characterized by erythematous psoriasiform plaques involving the nose, ears, and acral sites. Although classically associated with squamous cell carcinomas of the upper aerodigestive tract, it has also been reported in association with adenocarcinoma, genitourinary tumors, multiple myeloma, and rarely, peripheral T-cell lymphoma and follicular lymphoma in-situ. Herein, we present a patient with Bazex syndrome associated with angioimmunoblastic T-cell lymphoma (AITL), a rare association not previously reported in the literature. ","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46017461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.202
A. Gottlieb, R. Burge, W. Malatestinic, B. Zhu, Yunyang Zhao, J. McCormack, M. Kimel, M. Feely, J. Merola
{"title":"Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective","authors":"A. Gottlieb, R. Burge, W. Malatestinic, B. Zhu, Yunyang Zhao, J. McCormack, M. Kimel, M. Feely, J. Merola","doi":"10.25251/skin.7.supp.202","DOIUrl":"https://doi.org/10.25251/skin.7.supp.202","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42599592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Psoriasis is a known comorbid condition in patients with schizophrenia spectrum disorders. Due to the nature of these psychiatric conditions, many experience lengthy hospitalizations and self-isolate at baseline, which can make identification and management of psoriasis difficult. We report the case of a middle-aged male with a history of schizoaffective disorder and treatment-resistant psoriatic arthritis who experienced a severe flare while hospitalized. His two-month hospital stay became complicated by combative behavior and continued medication refusal, resulting in repeated seclusion events and eventual transfer to a higher acuity unit. After treatment with ixekizumab and a course of prednisone was initiated one month after admission and symptom onset, the patient’s lesions were tremendously improved along with his mood on the unit. With the improvement in his chronic pain and discomfort, the patient was able to focus on mental health recovery and rapidly approached discharge. This report highlights the importance of appropriate management of comorbid conditions, especially psoriasis in patients with schizophrenia spectrum disorders needing long-term hospitalization. Additionally, this case demonstrates the successful use of ixekizumab in treatment-resistant psoriasis.
{"title":"Psoriatic Arthritis Flare in a Hospitalized Patient with Schizoaffective Disorder: A Case Report","authors":"P. Arora, Tracy Tomac","doi":"10.25251/skin.7.3.12","DOIUrl":"https://doi.org/10.25251/skin.7.3.12","url":null,"abstract":"Psoriasis is a known comorbid condition in patients with schizophrenia spectrum disorders. Due to the nature of these psychiatric conditions, many experience lengthy hospitalizations and self-isolate at baseline, which can make identification and management of psoriasis difficult. We report the case of a middle-aged male with a history of schizoaffective disorder and treatment-resistant psoriatic arthritis who experienced a severe flare while hospitalized. His two-month hospital stay became complicated by combative behavior and continued medication refusal, resulting in repeated seclusion events and eventual transfer to a higher acuity unit. After treatment with ixekizumab and a course of prednisone was initiated one month after admission and symptom onset, the patient’s lesions were tremendously improved along with his mood on the unit. With the improvement in his chronic pain and discomfort, the patient was able to focus on mental health recovery and rapidly approached discharge. This report highlights the importance of appropriate management of comorbid conditions, especially psoriasis in patients with schizophrenia spectrum disorders needing long-term hospitalization. Additionally, this case demonstrates the successful use of ixekizumab in treatment-resistant psoriasis.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42827139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.213
M. Lebwohl, D. Rigel, T. Schlesinger, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, L. Kircik, Vishal Patel, Siva Narayanan, V. Koscielny, I. Kasujee
Introduction: The objective of this analysis was to compare patient and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis (AK) treated with tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AKs on the face or scalp who were newly initiated with once-daily tirbanibulin treatment (5-day course) in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, Week-8 (timeframe for main endpoints) and Week-24. Patient’s self-reported satisfaction and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area at individual patient-level were assessed among study patients at Week-8 on a seven-point adjectival response scale of 1 (extremely dissatisfied) – 7 (extremely satisfied). Results: A total of 290 patients with AKs completed the study assessments at Week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). Patient self-reported skin-texture at baseline was – dry: 39.66%, smooth: 47.59%, rough: 19.66%, bumpy: 18.62%, scaly: 35.17%, blistering/peeling: 6.55%. All patients (100%) completed their 5-day once-daily treatment course. At Week-8, 75.86% & 78.97% of the patients and clinicians respectively reported extremely/very/satisfied with tirbanibulin’s ability to improve ‘how skin looks’, while 14.14% & 14.14% respectively reported somewhat satisfied, and 10.00% & 6.55% respectively reported extremely/very/dissatisfied. At Week-8, 74.83% & 80.69% of patients and clinicians respectively reported extremely/very/satisfied with tirbanibulin’s ability to improve their ‘skin texture’, while 15.52% & 12.41% respectively reported somewhat satisfied, and 9.65% & 6.55% respectively reported extremely/very/dissatisfied. Conclusion: A majority of patients with AKs and their clinicians reported satisfaction with the ability of 5-day treatment course of tirbanibulin to improve ‘how skin looks’ or ‘skin texture’ in the tirbanibulin-treated area, at Week-8.
{"title":"Comparison of patient and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis treated with tirbanibulin in community practices across U.S.","authors":"M. Lebwohl, D. Rigel, T. Schlesinger, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, L. Kircik, Vishal Patel, Siva Narayanan, V. Koscielny, I. Kasujee","doi":"10.25251/skin.7.supp.213","DOIUrl":"https://doi.org/10.25251/skin.7.supp.213","url":null,"abstract":"Introduction: The objective of this analysis was to compare patient and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis (AK) treated with tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AKs on the face or scalp who were newly initiated with once-daily tirbanibulin treatment (5-day course) in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, Week-8 (timeframe for main endpoints) and Week-24. Patient’s self-reported satisfaction and clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area at individual patient-level were assessed among study patients at Week-8 on a seven-point adjectival response scale of 1 (extremely dissatisfied) – 7 (extremely satisfied). Results: A total of 290 patients with AKs completed the study assessments at Week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). Patient self-reported skin-texture at baseline was – dry: 39.66%, smooth: 47.59%, rough: 19.66%, bumpy: 18.62%, scaly: 35.17%, blistering/peeling: 6.55%. All patients (100%) completed their 5-day once-daily treatment course. At Week-8, 75.86% & 78.97% of the patients and clinicians respectively reported extremely/very/satisfied with tirbanibulin’s ability to improve ‘how skin looks’, while 14.14% & 14.14% respectively reported somewhat satisfied, and 10.00% & 6.55% respectively reported extremely/very/dissatisfied. At Week-8, 74.83% & 80.69% of patients and clinicians respectively reported extremely/very/satisfied with tirbanibulin’s ability to improve their ‘skin texture’, while 15.52% & 12.41% respectively reported somewhat satisfied, and 9.65% & 6.55% respectively reported extremely/very/dissatisfied. Conclusion: A majority of patients with AKs and their clinicians reported satisfaction with the ability of 5-day treatment course of tirbanibulin to improve ‘how skin looks’ or ‘skin texture’ in the tirbanibulin-treated area, at Week-8.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46288563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher Nguyen, Q. Nguyen, Kyle C. Lauck, Adelaide Hebert
Objectives: A discrepancy exists in the geographical distribution of dermatologists across the United States (US). The aim of this study was to reexamine the current geographical density of dermatologists to describe any changes compared to date from 5 and 12 years ago. Methods: Membership data from the 2021 American Academy of Dermatology (AAD) database were retrieved to characterize the distribution of dermatologists in 3-digit zip code areas. Results: Out of 712 populated zip codes with dermatologists, 510 (71.6%) had less than 4 dermatologists per 100,000, as compared to 515 (72.3%) in 2016 (– 0.19% CAGR). The dermatologist density of the 100 most populated areas (M = 4.5 dermatologists per 100,000, SD = 3.3) and 100 least populated areas (M = 1.6 dermatologists per 100,000, SD = 6.2) were significantly different (P < 0.0001). Conclusion: This analysis provides continued trends to compare to previous studies performed in 2016 and 2009. The highest and lowest density areas were similar to results from previous studies. The results indicate an enduring and significant maldistribution of dermatologists in the US.
{"title":"Five Years Later: Continuing Disparity in the Geographic Density and Distribution of U.S. Dermatologists","authors":"Christopher Nguyen, Q. Nguyen, Kyle C. Lauck, Adelaide Hebert","doi":"10.25251/skin.7.3.9","DOIUrl":"https://doi.org/10.25251/skin.7.3.9","url":null,"abstract":"Objectives: A discrepancy exists in the geographical distribution of dermatologists across the United States (US). The aim of this study was to reexamine the current geographical density of dermatologists to describe any changes compared to date from 5 and 12 years ago. \u0000Methods: Membership data from the 2021 American Academy of Dermatology (AAD) database were retrieved to characterize the distribution of dermatologists in 3-digit zip code areas. \u0000Results: Out of 712 populated zip codes with dermatologists, 510 (71.6%) had less than 4 dermatologists per 100,000, as compared to 515 (72.3%) in 2016 (– 0.19% CAGR). The dermatologist density of the 100 most populated areas (M = 4.5 dermatologists per 100,000, SD = 3.3) and 100 least populated areas (M = 1.6 dermatologists per 100,000, SD = 6.2) were significantly different (P < 0.0001). \u0000Conclusion: This analysis provides continued trends to compare to previous studies performed in 2016 and 2009. The highest and lowest density areas were similar to results from previous studies. The results indicate an enduring and significant maldistribution of dermatologists in the US.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" May","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41251564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.212
D. Rigel, M. Lebwohl, T. Schlesinger, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, L. Kircik, Vishal Patel, Siva Narayanan, V. Koscielny, I. Kasujee
Objectives: Actinic Keratosis (AK) has been shown to negatively affect emotional functioning and skin-related quality of life of patients. Impact of tirbanibulin treatment in alleviating AK disease burden in patients with AKs is not adequately understood. Objective of the analysis is to evaluate changes in patient-reported AK symptoms, emotions, and functioning, among patients with AKs treated with tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AKs on the face or scalp who were newly initiated with tirbanibulin treatment in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, week-8 (timeframe for main endpoints) and week-24. Skindex-16, completed at baseline and week-8, is a 16-item survey with 3 domains: symptoms (items 1-4), emotions (items 5-11) and functioning (items 12-16), with each item scored on a seven-point adjectival response scale, with a potential score of 0 (never bothered) to 6 (always bothered). Changes from baseline in proportion of patients reporting a score of 0 or 1 (never or least bothered; i.e., least disease burden) was analyzed for all Skindex-16 items at week-8. Results: A total of 290 patients with AKs completed the study assessments at week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). Patient self-reported skin-texture was – dry: 39.66%, smooth: 47.59%, rough: 19.66%, bumpy: 18.62%, scaly: 35.17%, blistering/peeling: 6.55%. Within symptoms domain of Skindex-16 related to itching, burning/stinging, hurting, and irritation, proportion of patients reporting “never or least bothered” increased significantly for each item at week-8 (p<0.0001). Within emotions domain of Skindex-16 related to persistence of condition, worries about skin, appearance, frustration, embarrassment, being annoyed, and feeling depressed, proportion of patients reporting “never or least bothered” increased significantly for each item at week-8 (p<0.0001). Within functioning domain of Skindex-16 related to interactions with others, desire to be with others, show affection, effect on daily activities, and effect on work or enjoyable activities, proportion of patients reporting “never or least bothered” increased significantly for each item at week-8 (p<0.0001). Conclusion: Patients with AKs who used once-daily tirbanibulin treatment for 5-days reported a significant reduction in the AK burden, as indicated by the improvement in AK symptoms and emotional/functional impact, at week-8.
{"title":"Impact of Actinic Keratosis on patient-reported AK symptoms, emotions and functioning measured using Skindex-16, among patients with Actinic Keratosis administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)","authors":"D. Rigel, M. Lebwohl, T. Schlesinger, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, L. Kircik, Vishal Patel, Siva Narayanan, V. Koscielny, I. Kasujee","doi":"10.25251/skin.7.supp.212","DOIUrl":"https://doi.org/10.25251/skin.7.supp.212","url":null,"abstract":"Objectives: Actinic Keratosis (AK) has been shown to negatively affect emotional functioning and skin-related quality of life of patients. Impact of tirbanibulin treatment in alleviating AK disease burden in patients with AKs is not adequately understood. Objective of the analysis is to evaluate changes in patient-reported AK symptoms, emotions, and functioning, among patients with AKs treated with tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AKs on the face or scalp who were newly initiated with tirbanibulin treatment in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, week-8 (timeframe for main endpoints) and week-24. Skindex-16, completed at baseline and week-8, is a 16-item survey with 3 domains: symptoms (items 1-4), emotions (items 5-11) and functioning (items 12-16), with each item scored on a seven-point adjectival response scale, with a potential score of 0 (never bothered) to 6 (always bothered). Changes from baseline in proportion of patients reporting a score of 0 or 1 (never or least bothered; i.e., least disease burden) was analyzed for all Skindex-16 items at week-8. Results: A total of 290 patients with AKs completed the study assessments at week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). Patient self-reported skin-texture was – dry: 39.66%, smooth: 47.59%, rough: 19.66%, bumpy: 18.62%, scaly: 35.17%, blistering/peeling: 6.55%. Within symptoms domain of Skindex-16 related to itching, burning/stinging, hurting, and irritation, proportion of patients reporting “never or least bothered” increased significantly for each item at week-8 (p<0.0001). Within emotions domain of Skindex-16 related to persistence of condition, worries about skin, appearance, frustration, embarrassment, being annoyed, and feeling depressed, proportion of patients reporting “never or least bothered” increased significantly for each item at week-8 (p<0.0001). Within functioning domain of Skindex-16 related to interactions with others, desire to be with others, show affection, effect on daily activities, and effect on work or enjoyable activities, proportion of patients reporting “never or least bothered” increased significantly for each item at week-8 (p<0.0001). Conclusion: Patients with AKs who used once-daily tirbanibulin treatment for 5-days reported a significant reduction in the AK burden, as indicated by the improvement in AK symptoms and emotional/functional impact, at week-8.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46336036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michela Salusti-Simpson, Hannah Porter, Dustin L Taylor, Evan W. Piette
Blastomycosis-like pyoderma (BLP) is a rare cutaneous disorder that results from an exaggerated response to a bacterial infection, most commonly Staphylococcus aureus. There are a variety of reported predisposing factors, including diabetes, obesity, leukemia, primary immunodeficiency, and immunomodulatory therapy. Clinical and histopathological findings of BLP can be quite disparate, often resulting in a delay in diagnosis. We report here a case of a man who presented with an enlarging verrucous nodule of his neck, and was subsequently diagnosed with BLP. The purpose of sharing this case is to contribute to the existing literature of this rare disease by highlighting a unique presentation.
{"title":"Blastomycosis-Like Pyoderma in a 59-year-old Male with Type 2 Diabetes Mellitus","authors":"Michela Salusti-Simpson, Hannah Porter, Dustin L Taylor, Evan W. Piette","doi":"10.25251/skin.7.3.17","DOIUrl":"https://doi.org/10.25251/skin.7.3.17","url":null,"abstract":"Blastomycosis-like pyoderma (BLP) is a rare cutaneous disorder that results from an exaggerated response to a bacterial infection, most commonly Staphylococcus aureus. There are a variety of reported predisposing factors, including diabetes, obesity, leukemia, primary immunodeficiency, and immunomodulatory therapy. Clinical and histopathological findings of BLP can be quite disparate, often resulting in a delay in diagnosis. We report here a case of a man who presented with an enlarging verrucous nodule of his neck, and was subsequently diagnosed with BLP. The purpose of sharing this case is to contribute to the existing literature of this rare disease by highlighting a unique presentation.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46790908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.205
R. Chovatiya, S. Balu, Yestle Kim, Amanda G. Althoff, L. Rasouliyan
{"title":"Early Insights into the Characteristics of Tralokinumab Patients in a Real-World Setting in the United States","authors":"R. Chovatiya, S. Balu, Yestle Kim, Amanda G. Althoff, L. Rasouliyan","doi":"10.25251/skin.7.supp.205","DOIUrl":"https://doi.org/10.25251/skin.7.supp.205","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48358027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joseph H. Haquang, Rock Li, K. Mai, Kuang Cheng Chen, Fardad Sisan, Kuo YuLing
Background: Sebaceous carcinoma is a rare and potentially aggressive cutaneous malignancy. It is derived from the adnexal epithelium of sebaceous glands and tends to hold a diverse clinical presentation. Although it is often reported in the periocular region, it can manifest from any sebaceous unit in the skin. Due to the rarity of this condition, prognostic and demographic factors are largely indeterminate. Hence, we sought to assess the prognostic impact of demographic and socioeconomic factors on the outcome of patients with sebaceous carcinoma. Methods: A retrospective analysis was performed utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database. From the registries, cases of sebaceous carcinoma from the years 2000 to 2018 were analyzed. Univariate and multivariate cox regression analyses were used to analyze the significance of socioeconomic and demographic factors on the survival of sebaceous carcinoma. Tumor grade and extent were included in the multivariate cox regression to minimize confounding. Results: A total of 4154 cases of sebaceous carcinoma were analyzed within this study. Socioeconomic and demographic factors analyzed includes age, sex, race, and income. On multivariate analysis including tumor grade, tumor extent, age, sex, race and income, African American race was a significant risk indicator for survival (hazard ratio [HR], 1.9; P=.007). Increased age of 70+ were also identified as a significant risk indicator for survival (HR, 5.86; P<0.001). Female sex was identified as a protective indicator for survival (HR, 0.82; P=0.03). Income status did not significantly influence the survival outcome of sebaceous carcinoma. Conclusion: Although income status did not show any significant influence on the survival outcome of sebaceous carcinoma, sex, race, and age characteristics did. The etiology behind these prognostic factors is unclear but may be related to access to medical care or lack of social support.
{"title":"Epidemiology and Mortality Risk Factors of Sebaceous Carcinoma: A SEER – Based Population Study","authors":"Joseph H. Haquang, Rock Li, K. Mai, Kuang Cheng Chen, Fardad Sisan, Kuo YuLing","doi":"10.25251/skin.7.3.4","DOIUrl":"https://doi.org/10.25251/skin.7.3.4","url":null,"abstract":"Background: \u0000Sebaceous carcinoma is a rare and potentially aggressive cutaneous malignancy. It is derived from the adnexal epithelium of sebaceous glands and tends to hold a diverse clinical presentation. Although it is often reported in the periocular region, it can manifest from any sebaceous unit in the skin. Due to the rarity of this condition, prognostic and demographic factors are largely indeterminate. Hence, we sought to assess the prognostic impact of demographic and socioeconomic factors on the outcome of patients with sebaceous carcinoma. \u0000 \u0000Methods: \u0000A retrospective analysis was performed utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database. From the registries, cases of sebaceous carcinoma from the years 2000 to 2018 were analyzed. Univariate and multivariate cox regression analyses were used to analyze the significance of socioeconomic and demographic factors on the survival of sebaceous carcinoma. Tumor grade and extent were included in the multivariate cox regression to minimize confounding. \u0000 \u0000Results: \u0000A total of 4154 cases of sebaceous carcinoma were analyzed within this study. Socioeconomic and demographic factors analyzed includes age, sex, race, and income. On multivariate analysis including tumor grade, tumor extent, age, sex, race and income, African American race was a significant risk indicator for survival (hazard ratio [HR], 1.9; P=.007). Increased age of 70+ were also identified as a significant risk indicator for survival (HR, 5.86; P<0.001). Female sex was identified as a protective indicator for survival (HR, 0.82; P=0.03). Income status did not significantly influence the survival outcome of sebaceous carcinoma. \u0000 \u0000Conclusion: \u0000Although income status did not show any significant influence on the survival outcome of sebaceous carcinoma, sex, race, and age characteristics did. The etiology behind these prognostic factors is unclear but may be related to access to medical care or lack of social support. \u0000 ","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49583576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.201
A. Gottlieb, R. Burge, W. Malatestinic, B. Zhu, Yunyang Zhao, J. McCormack, M. Kimel, M. Feely, J. Merola
{"title":"Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program","authors":"A. Gottlieb, R. Burge, W. Malatestinic, B. Zhu, Yunyang Zhao, J. McCormack, M. Kimel, M. Feely, J. Merola","doi":"10.25251/skin.7.supp.201","DOIUrl":"https://doi.org/10.25251/skin.7.supp.201","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43096199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：